B
Borje S. Andersson
Researcher at University of Texas MD Anderson Cancer Center
Publications - 419
Citations - 19172
Borje S. Andersson is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Transplantation & Busulfan. The author has an hindex of 68, co-authored 401 publications receiving 17976 citations. Previous affiliations of Borje S. Andersson include University of Texas at Austin & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy
Sergio Giralt,Elihu H. Estey,Maher Albitar,Koen van Besien,Gabriela Rondon,Paolo Anderlini,Susan O'Brien,Issa F. Khouri,James Gajewski,Rakesh Mehra,David F. Claxton,Borje S. Andersson,Miloslav Beran,Donna Przepiorka,Charles Koller,Steve Kornblau,Martin Korbling,Michael J. Keating,Hagop M. Kantarjian,Richard E. Champlin +19 more
TL;DR: It is concluded that purine analog-containing nonmyeloablative regimens allow engraftment of HLA-compatible hematopoietic progenitor cells and warrants further study in patients with leukemia who are ineligible for conventional transplantation with myeloablatives either because of age or concurrent medical conditions.
Journal ArticleDOI
Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.
Issa F. Khouri,Michael J. Keating,M. Korbling,Donna Przepiorka,Paolo Anderlini,Susan O'Brien,Sergio Giralt,Cindy Ippoliti,B. Von Wolff,James Gajewski,M. Donato,David F. Claxton,Naoto T. Ueno,Borje S. Andersson,Adrian P. Gee,Richard E. Champlin +15 more
TL;DR: The ability to induce remissions with donor lymphocyte infusion in patients with CLL, Richter's, and low-grade and intermediate-grade lymphoma is direct evidence of GVL activity against lymphoid malignancies.
Journal ArticleDOI
Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
Sergio Giralt,Peter F. Thall,Issa F. Khouri,Xuemei Wang,Ira Braunschweig,Cindy Ippolitti,David F. Claxton,Michele L. Donato,J. Bruton,A. Cohen,Marilyn S. Davis,Borje S. Andersson,Paolo Anderlini,James Gajewski,Steven M. Kornblau,Michael Andreeff,Donna Przepiorka,Naoto T. Ueno,Jeffrey J. Molldrem,Richard E. Champlin +19 more
TL;DR: Fludarabine/melphalan combinations are feasible in older patients with associated comorbidities, and long-term disease control can be achieved with reduced-intensity conditioning in this population, according to multivariate analysis.
Journal ArticleDOI
Allogeneic Blood Stem Cell Transplantation for Refractory Leukemia and Lymphoma: Potential Advantage of Blood Over Marrow Allografts
Martin Korbling,Donna Przepiorka,Yang O. Huh,Heike Engel,K. Van Besien,Sergio Giralt,Borje S. Andersson,Hans Dieter Kleine,D. Seong,Albert B. Deisseroth +9 more
TL;DR: Cryopreserved, filgrastim-stimulated allogeneic PBSCs may be a suitable alternative to allogenic marrow for transplantation with the advantage of more rapid platelet recovery, and further studies are required to assess long-term risks of chronic GVHD.
Journal ArticleDOI
Cord-blood engraftment with ex vivo mesenchymal-cell coculture.
Marcos de Lima,Ian McNiece,Simon N. Robinson,Mark F. Munsell,Mary Eapen,Mary M. Horowitz,Amin M. Alousi,Rima M. Saliba,John McMannis,Indreshpal Kaur,Partow Kebriaei,Simrit Parmar,Uday R. Popat,Chitra Hosing,Richard E. Champlin,Catherine M. Bollard,Jeffrey J. Molldrem,Roy B. Jones,Yago Nieto,Borje S. Andersson,Nina Shah,Betul Oran,Laurence J.N. Cooper,Laura L. Worth,Muzaffar H. Qazilbash,Martin Korbling,Gabriela Rondon,Stefan O. Ciurea,Doyle Bosque,I. Maewal,Paul J. Simmons,Elizabeth J. Shpall +31 more
TL;DR: Transplantation of cord-blood cells expanded ex vivo in cocultures with allogeneic mesenchymal stromal cells appeared to be safe and effective and significantly improved engraftment, as compared with unmanipulated cord blood only.